Ausgabe 3/2021
Inhalt (7 Artikel)
Targeting β-Arrestins in the Treatment of Psychiatric and Neurological Disorders
Sharonda S. Harris, Nikhil M. Urs
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox–Gastaut Syndrome
Simona Lattanzi, Eugen Trinka, Pasquale Striano, Chiara Rocchi, Sergio Salvemini, Mauro Silvestrini, Francesco Brigo
Psychotropic Drug-Induced Glaucoma: A Practical Guide to Diagnosis and Management
Neeranjali S. Jain, Claire W. Ruan, Shanil R. Dhanji, Richard J. Symes
Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report
Trisha Chakrabarty, Shane J. McInerney, Ivan J. Torres, Benicio N. Frey, Roumen V. Milev, Daniel J. Müller, Susan Rotzinger, Sidney H. Kennedy, Raymond W. Lam
Effect of Enzyme-Inducing Antiseizure Medications on the Risk of Sub-Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study
Amichai Perlman, Rachel Goldstein, Lotan Choshen Cohen, Bruria Hirsh-Raccah, David Hakimian, Ilan Matok, Yosef Kalish, Daniel E. Singer, Mordechai Muszkat
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Anthony T. Reder, Diego Centonze, Maria L. Naylor, Anjali Nagpal, Rajani Rajbhandari, Arman Altincatal, Michelle Kim, Aaron Berdofe, Maha Radhakrishnan, Eunice Jung, Alfred W. Sandrock, Karen Smirnakis, Catrinel Popescu, Carl de Moor
First-in-Human Randomized Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the KDM1A Inhibitor Vafidemstat
Rosa María Antonijoan, Juan Manuel Ferrero-Cafiero, Jimena Coimbra, Montse Puntes, Joan Martínez-Colomer, María Isabel Arévalo, Cristina Mascaró, Cesar Molinero, Carlos Buesa, Tamara Maes